The global hyperpigmentation treatment market, valued at $1.52 billion in 2025, is projected to grow to $2.85 billion by 2035 at a CAGR of 6.5%. Growth is fueled by rising consumer awareness of skin aesthetics, increasing cases of pigmentation disorders like melasma and post-inflammatory hyperpigmentation, and demand for advanced treatments such as laser therapy, chemical peels, and microneedling. North America leads the market, with the U.S. expected to reach $0.93 billion by 2035. Asia-Pacific is the fastest-growing region due to rising incomes and beauty consciousness. Key players include AbbVie, L'Oréal, and Johnson & Johnson.
AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global ch...
In a Phase 2a study, ABBV-466, a dual-targeting therapy by AbbVie, achieved significantly higher endoscopic remission rates in Crohn's disease patients at Week 12 compared to anti-IL-23 p19 or anti-α4β7 monotherapies. The remission advantage increase...
At the 2026 European Society for Medical Oncology (ESMO) Congress, AbbVie presented new and updated data on its oncology portfolio, including investigational drugs like Temab-A, ABBV-706, and ABBV-969. These drugs showed encouraging clinical activity...
AbbVie increased its quarterly dividend to $1.73, raising its annual payout by 5.5% despite a 29% stock price rise this year, which lowers the yield to about 2.4%. The company’s dividend payout ratio is around 49.5% of adjusted earnings, supported by...
AbbVie unveiled 20 new scientific presentations at the 2026 United European Gastroenterology Week, highlighting long-term and real-world data for its inflammatory bowel disease (IBD) treatments SKYRIZI (risankizumab) and RINVOQ (upadacitinib). The da...
